Captopril
Captopril, sold under the brand name Capoten among others, is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first oral ACE inhibitor found for the treatment of hypertension. It does not cause fatigue as associated with beta-blockers. Due to the adverse drug event of causing hyperkalemia, as seen with most ACE Inhibitors, the medication is usually paired with a diuretic.
Clinical data | |
---|---|
Pronunciation | /ˈkæptəprɪl/ |
Trade names | Capoten, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682823 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 70–75% |
Metabolism | Liver |
Elimination half-life | 1.9 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.057.806 |
Chemical and physical data | |
Formula | C9H15NO3S |
Molar mass | 217.28 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(verify) |
Captopril was patented in 1976 and approved for medical use in 1980.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.